207 related articles for article (PubMed ID: 30314802)
1. JCL roundtable: High-density lipoprotein function and reverse cholesterol transport.
Cuchel M; Rohatgi A; Sacks FM; Guyton JR
J Clin Lipidol; 2018; 12(5):1086-1094. PubMed ID: 30314802
[TBL] [Abstract][Full Text] [Related]
2. ApoE and apoC-III-defined HDL subtypes: a descriptive study of their lecithin cholesterol acyl transferase and cholesteryl ester transfer protein content and activity.
Amaya-Montoya M; Pinzón-Cortés JA; Silva-Bermúdez LS; Ruiz-Manco D; Pérez-Matos MC; Jiménez-Mora MA; Mendivil CO
Lipids Health Dis; 2020 May; 19(1):106. PubMed ID: 32450892
[TBL] [Abstract][Full Text] [Related]
3. Increased atherosclerosis in mice lacking apolipoprotein A-I attributable to both impaired reverse cholesterol transport and increased inflammation.
Moore RE; Navab M; Millar JS; Zimetti F; Hama S; Rothblat GH; Rader DJ
Circ Res; 2005 Oct; 97(8):763-71. PubMed ID: 16151025
[TBL] [Abstract][Full Text] [Related]
4. High-density lipoprotein revisited: biological functions and clinical relevance.
von Eckardstein A; Nordestgaard BG; Remaley AT; Catapano AL
Eur Heart J; 2023 Apr; 44(16):1394-1407. PubMed ID: 36337032
[TBL] [Abstract][Full Text] [Related]
5. High density lipoprotein structure-function and role in reverse cholesterol transport.
Lund-Katz S; Phillips MC
Subcell Biochem; 2010; 51():183-227. PubMed ID: 20213545
[TBL] [Abstract][Full Text] [Related]
6. Enhanced atheroprotection and lesion remodelling by targeting the foam cell and increasing plasma cholesterol acceptors.
Son SH; Goo YH; Choi M; Saha PK; Oka K; Chan LC; Paul A
Cardiovasc Res; 2016 Feb; 109(2):294-304. PubMed ID: 26487692
[TBL] [Abstract][Full Text] [Related]
7. Age-associated decrease of high-density lipoprotein-mediated reverse cholesterol transport activity.
Berrougui H; Khalil A
Rejuvenation Res; 2009 Apr; 12(2):117-26. PubMed ID: 19405812
[TBL] [Abstract][Full Text] [Related]
8. Cholesterol efflux capacity, high-density lipoprotein function, and atherosclerosis.
Khera AV; Cuchel M; de la Llera-Moya M; Rodrigues A; Burke MF; Jafri K; French BC; Phillips JA; Mucksavage ML; Wilensky RL; Mohler ER; Rothblat GH; Rader DJ
N Engl J Med; 2011 Jan; 364(2):127-35. PubMed ID: 21226578
[TBL] [Abstract][Full Text] [Related]
9. Apolipoprotein A-II is a key regulatory factor of HDL metabolism as appears from studies with transgenic animals and clinical outcomes.
Maïga SF; Kalopissis AD; Chabert M
Biochimie; 2014 Jan; 96():56-66. PubMed ID: 24012775
[TBL] [Abstract][Full Text] [Related]
10. Plasma turnover of HDL apoC-I, apoC-III, and apoE in humans: in vivo evidence for a link between HDL apoC-III and apoA-I metabolism.
Cohn JS; Batal R; Tremblay M; Jacques H; Veilleux L; Rodriguez C; Mamer O; Davignon J
J Lipid Res; 2003 Oct; 44(10):1976-83. PubMed ID: 12867543
[TBL] [Abstract][Full Text] [Related]
11. Modulation of high-density lipoprotein cholesterol metabolism and reverse cholesterol transport.
Hersberger M; von Eckardstein A
Handb Exp Pharmacol; 2005; (170):537-61. PubMed ID: 16596814
[TBL] [Abstract][Full Text] [Related]
12. The novel selective PPARα modulator (SPPARMα) pemafibrate improves dyslipidemia, enhances reverse cholesterol transport and decreases inflammation and atherosclerosis.
Hennuyer N; Duplan I; Paquet C; Vanhoutte J; Woitrain E; Touche V; Colin S; Vallez E; Lestavel S; Lefebvre P; Staels B
Atherosclerosis; 2016 Jun; 249():200-8. PubMed ID: 27108950
[TBL] [Abstract][Full Text] [Related]
13. Liver ABCA1 deletion in LDLrKO mice does not impair macrophage reverse cholesterol transport or exacerbate atherogenesis.
Bi X; Zhu X; Duong M; Boudyguina EY; Wilson MD; Gebre AK; Parks JS
Arterioscler Thromb Vasc Biol; 2013 Oct; 33(10):2288-96. PubMed ID: 23814116
[TBL] [Abstract][Full Text] [Related]
14. HDL cholesterol efflux capacity and incident cardiovascular events.
Rohatgi A; Khera A; Berry JD; Givens EG; Ayers CR; Wedin KE; Neeland IJ; Yuhanna IS; Rader DR; de Lemos JA; Shaul PW
N Engl J Med; 2014 Dec; 371(25):2383-93. PubMed ID: 25404125
[TBL] [Abstract][Full Text] [Related]
15. High-density lipoproteins in the prevention of cardiovascular disease: changing the paradigm.
Tuteja S; Rader DJ
Clin Pharmacol Ther; 2014 Jul; 96(1):48-56. PubMed ID: 24713591
[TBL] [Abstract][Full Text] [Related]
16. The dual nature of HDL: Anti-Inflammatory and pro-Inflammatory.
Namiri-Kalantari R; Gao F; Chattopadhyay A; Wheeler AA; Navab KD; Farias-Eisner R; Reddy ST
Biofactors; 2015 May; 41(3):153-9. PubMed ID: 26072738
[TBL] [Abstract][Full Text] [Related]
17. [Role of HDL in Cholesterol Efflux and Reverse Cholesterol Transport].
Ayaori M
Rinsho Byori; 2016 Jan; 64(1):57-65. PubMed ID: 27192798
[TBL] [Abstract][Full Text] [Related]
18. Reverse cholesterol transport and cholesterol efflux in atherosclerosis.
Ohashi R; Mu H; Wang X; Yao Q; Chen C
QJM; 2005 Dec; 98(12):845-56. PubMed ID: 16258026
[TBL] [Abstract][Full Text] [Related]
19. High density lipoprotein deficiency with xanthomas. A defect in reverse cholesterol transport caused by a point mutation in the apolipoprotein A-I gene.
Lackner KJ; Dieplinger H; Nowicka G; Schmitz G
J Clin Invest; 1993 Nov; 92(5):2262-73. PubMed ID: 7693760
[TBL] [Abstract][Full Text] [Related]
20. High-density lipoprotein function, dysfunction, and reverse cholesterol transport.
Fisher EA; Feig JE; Hewing B; Hazen SL; Smith JD
Arterioscler Thromb Vasc Biol; 2012 Dec; 32(12):2813-20. PubMed ID: 23152494
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
